Dynamic microRNA Signatures as Biomarkers for Cardiac Ischemia and Remodeling
Abstract
1. Introduction
2. Results
2.1. In Vivo Permanent Occlusion Rat Model Reproduces Heart Failure: Characterization of Tissue Alterations During Occlusion
2.2. Serum miRNA Levels Decrease at 24 h in Permanent Occlusion Rats
2.3. miRNA Expression Increases at 72 h of Permanent Occlusion in Heart Tissue
2.4. Upregulation of Fibronectin, Collagen, E-Cadherin and Vimentin at 72 h Contrasts with Transient VEGF Downregulation After Permanent Coronary Occlusion
3. Discussion
4. Materials and Methods
4.1. Permanent Occlusion Rat Model
4.2. Troponin Measure
4.3. Hematoxylin and Eosin, Evans Blue and TTC Staining
4.4. Masson’s Staining
4.5. Immunohistochemistry Protocol
4.6. RNA Isolation from Rat Serum and Heart Tissues
4.7. RT-qPCR for miRNAs and Genes from Serum and Heart Rat Tissues
4.8. Statistical Analysis
4.9. Study Limitations
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
Abbreviations
| ACS | Acute Coronary Syndrome |
| α-SMA | Alpha-Smooth-Muscle Actin |
| AMPKα2 | AMP-Activated Protein Kinase alpha-2 subunit |
| BMDMs | Bone-Marrow-Derived Macrophages |
| BSA | Bovine Serum Albumin |
| CMIA | Chemiluminescent Microparticle Immunoassay |
| Ct | Cycle threshold (qPCR read-out) |
| CVD | Cardiovascular Diseases |
| CXCL12 | C-X-C Motif Chemokine Ligand 12 |
| DAB | 3,3′-Diaminobenzidine (chromogen) |
| DMEM | Dulbecco’s Modified Eagle Medium |
| FBS | Fetal Bovine Serum |
| HBSS | Hanks’ Balanced Salt Solution |
| H&E | Hematoxylin & Eosin (histology stain) |
| HIF-1α | Hypoxia-Inducible Factor 1-alpha |
| LAD/LDA | Left (Anterior) Descending Coronary Artery (rat ligation site) |
| MCP1 | Monocyte Chemoattractant Protein 1 |
| miRNA | MicroRNA (noncoding regulatory RNA) |
| MI | Myocardial Infarction |
| MZB | Marginal-Zone B (lymphocyte) |
| PBS | Phosphate-Buffered Saline |
| (RT)-qPCR | (Reverse-Transcription) Quantitative Polymerase Chain Reaction |
| RLU | Relative Light Units (chemiluminescence read-out) |
| ROS | Reactive Oxygen Species |
| SEM | Standard Error of the Mean |
| SPSS | Statistical Package for the Social Sciences (software) |
| TNF-α | Tumor Necrosis Factor alpha |
| TTC | 2,3,5-Triphenyltetrazolium Chloride (infarct stain) |
| VEGF | Vascular Endothelial Growth Factor |
Appendix A
| Histology | Sham | 24 h | 72 h | 7 Days | 1 Month |
|---|---|---|---|---|---|
| Architecture | Preserve | Preserve | Altered and inflammatory infiltrate (3) | Altered by necrosis and inflammatory infiltrate (2) | Altered by fibrosis and inflammatory infiltrate (1) |
| Fiber disorganization | Absent | Absent | Absent | Absent, fibrosis (2) | Present, focal fibrosis (3) |
| Epicardium cellularity | Normal | Cellularity increase | High cellularity increase | Cellularity increase | Cellularity increase |
| Endocardium | Normal | Normal | Focal affectation | Focal affectation | Normal |
| Myocytes | Matures | Matures | Replaced by inflammatory infiltrate. Necrotic myocytes (3) | Replaced by inflammatory infiltrate: chronic hurt. Necrotic myocytes (2) | Replaced by inflammatory infiltrate and fibrosis. |
| Nuclei | Low variability | Low variability: hyper eosinophilia and pyknosis, focal | Disappeared in focal areas | Disappeared in focal areas | Disappeared in focal areas |
| Interstice | Normal | Normal/lightly cellularity increase | Inflammation: acute and chronic pain (3). Necrosis (4) and haemorrhage | Chronic inflammation (3) and necrotic myocytes (2) | Chronic inflammation (2) |
| New vascularity | No, normal | No, normal | Increased vessels (2) in inflammatory areas | Highly increased vessels (3) in inflammatory areas | Lightly increased vessels (1) in inflammatory areas |
| Feature | Scoring System (Semi-Quantitative) | Methodology/Markers | References |
|---|---|---|---|
| Necrosis | 0 = none; 1 ≤ 25% of segment; 2 = 26–50%; 3 = 51–75%; 4 = 76–100% (transmurality per segment) | TTC staining (histology); LGE-CMR segmental hyperenhancement | [44,45] |
| Fibrosis | 0 = none; 1 = mild; 2 = moderate; 3 = severe (based on % area or intensity) | Masson’s trichrome (histology); LGE-CMR (signal thresholding, e.g., >5 SD above remote myocardium) | [44,46] |
| Neovascularization | 0 = none; 1 = rare; 2 = moderate; 3 = extensive (count per high-power field or area) | CD31/CD34 immunostaining (histology); not routinely quantified by CMR | [44] |
| Inflammation | 0 = none; 1 = mild; 2 = moderate; 3 = severe (inflammatory cell count per high-power field) | H&E (histology); T2-weighted CMR (edema as surrogate for inflammation, >2 SD above remote myocardium) | [44] |

References
- Global Burden of Cardiovascular Diseases and Risks 2023 Collaborators. Global, Regional, and National Burden of Cardiovascular Diseases and Risk Factors in 204 Countries and Territories, 1990–2023. J. Am. Coll. Cardiol. 2025, 86, 2167–2243. [CrossRef]
- Aikawa, M.; Sonawane, A.R.; Chelvanambi, S.; Asano, T.; Halu, A.; Matamalas, J.T.; Singh, S.A.; Uchida, S.; Aikawa, E.; Arenas, A.; et al. Precision cardiovascular medicine: Shifting the innovation paradigm. Front. Sci. 2025, 3, 1474469. [Google Scholar] [CrossRef]
- Kraler, S.; Mueller, C.; Libby, P.; Bhatt, D.L. Acute coronary syndromes: Mechanisms, challenges, and new opportunities. Eur. Heart J. 2025, 46, 2866–2889. [Google Scholar] [CrossRef] [PubMed]
- Kimura, K.; Kimura, T.; Ishihara, M.; Nakagawa, Y.; Nakao, K.; Miyauchi, K.; Sakamoto, T.; Tsujita, K.; Hagiwara, N.; Miyazaki, S.; et al. JCS 2018 Guideline on Diagnosis and Treatment of Acute Coronary Syndrome. Circ. J. Off. J. Jpn. Circ. Soc. 2019, 83, 1085–1196. [Google Scholar] [CrossRef] [PubMed]
- Saha, T.; Soliman-Aboumarie, H. Review of Current Management of Myocardial Infarction. J. Clin. Med. 2025, 14, 6241. [Google Scholar] [CrossRef]
- Mechanic, O.J.; Gavin, M.; Grossman, S.A. Acute Myocardial Infarction. In StatPearls; StatPearls Publishing: Treasure Island, FL, USA, 2025. Available online: http://www.ncbi.nlm.nih.gov/books/NBK459269/ (accessed on 10 October 2025).
- Wang, L.; Jin, Y. Noncoding RNAs as Biomarkers for Acute Coronary Syndrome. BioMed Res. Int. 2020, 2020, 3298696. [Google Scholar] [CrossRef] [PubMed]
- Rincón, L.M.; Rodríguez-Serrano, M.; Conde, E.; Lanza, V.F.; Sanmartín, M.; González-Portilla, P.; Paz-García, M.; Del Rey, J.M.; Menacho, M.; García Bermejo, M.-L.; et al. Serum microRNAs are key predictors of long-term heart failure and cardiovascular death after myocardial infarction. ESC Heart Fail. 2022, 9, 3367–3379. [Google Scholar] [CrossRef]
- Correia de Sousa, M.; Gjorgjieva, M.; Dolicka, D.; Sobolewski, C.; Foti, M. Deciphering miRNAs’ Action through miRNA Editing. Int. J. Mol. Sci. 2019, 20, 6249. [Google Scholar] [CrossRef]
- Rahul, K.; Kumar, S.; Kumar, B.; Chaudhary, V.; Rahul, K.; Kumar, S.; Kumar, B.; Chaudhary, V. Circulating microRNAs as potential novel biomarkers in cardiovascular diseases: Emerging role, biogenesis, current knowledge, therapeutics and the road ahead. Int. J. Cardiovasc. Acad. 2022, 8, 31–40. [Google Scholar] [CrossRef]
- Zhou, S.; Jin, J.; Wang, J.; Zhang, Z.; Freedman, J.H.; Zheng, Y.; Cai, L. miRNAS in cardiovascular diseases: Potential biomarkers, therapeutic targets and challenges. Acta Pharmacol. Sin. 2018, 39, 1073–1084. [Google Scholar] [CrossRef]
- Gong, X.; Wu, G.; Zeng, C. Role of circular RNAs in cardiovascular diseases. Exp. Biol. Med. 2019, 244, 73–82. [Google Scholar] [CrossRef] [PubMed]
- Varzideh, F.; Kansakar, U.; Donkor, K.; Wilson, S.; Jankauskas, S.S.; Mone, P.; Wang, X.; Lombardi, A.; Santulli, G. Cardiac Remodeling After Myocardial Infarction: Functional Contribution of microRNAs to Inflammation and Fibrosis. Front. Cardiovasc. Med. 2022, 9, 863238. [Google Scholar] [CrossRef] [PubMed]
- Buja, L.M. Pathobiology of Myocardial Ischemia and Reperfusion Injury: Models, Modes, Molecular Mechanisms, Modulation, and Clinical Applications. Cardiol. Rev. 2023, 31, 252–264. [Google Scholar] [CrossRef] [PubMed]
- Marin, W.; Marin, D.; Ao, X.; Liu, Y. Mitochondria as a therapeutic target for cardiac ischemia-reperfusion injury (Review). Int. J. Mol. Med. 2021, 47, 485–499. [Google Scholar] [CrossRef]
- Gumpper-Fedus, K.; Park, K.H.; Ma, H.; Zhou, X.; Bian, Z.; Krishnamurthy, K.; Sermersheim, M.; Zhou, J.; Tan, T.; Li, L.; et al. MG53 preserves mitochondrial integrity of cardiomyocytes during ischemia reperfusion-induced oxidative stress. Redox Biol. 2022, 54, 102357. [Google Scholar] [CrossRef]
- Li, T.; Yan, Z.; Fan, Y.; Fan, X.; Li, A.; Qi, Z.; Zhang, J. Cardiac repair after myocardial infarction: A two-sided role of inflammation-mediated. Front. Cardiovasc. Med. 2023, 9, 1077290. [Google Scholar] [CrossRef]
- Kubota, A.; Frangogiannis, N.G. Macrophages in myocardial infarction. Am. J. Physiol.-Cell Physiol. 2022, 323, C1304–C1324. [Google Scholar] [CrossRef]
- Dölling, M.; Eckstein, M.; Singh, J.; Schauer, C.; Schoen, J.; Shan, X.; Bozec, A.; Knopf, J.; Schett, G.; Muñoz, L.E.; et al. Hypoxia Promotes Neutrophil Survival After Acute Myocardial Infarction. Front. Immunol. 2022, 13, 726153. [Google Scholar] [CrossRef]
- Lindsey, M.L.; Oliver, A.F.; Gaye, A.; Nde, P.N.; DeLeon-Pennell, K.Y.; González, G.E. Cellular Interactions of Cardiac Repair After Myocardial Infarction. Cells 2025, 14, 1903. [Google Scholar] [CrossRef]
- Liu, J.; Yang, C.; Liu, T.; Deng, Z.; Fang, W.; Zhang, X.; Li, J.; Huang, Q.; Liu, C.; Wang, Y.; et al. Eosinophils improve cardiac function after myocardial infarction. Nat. Commun. 2020, 11, 6396. [Google Scholar] [CrossRef]
- Chalise, U.; Becirovic-Agic, M.; Lindsey, M.L. Neutrophil crosstalk during cardiac wound healing after myocardial infarction. Curr. Opin. Physiol. 2021, 24, 100485. [Google Scholar] [CrossRef] [PubMed]
- Jian, Y.; Zhou, X.; Shan, W.; Chen, C.; Ge, W.; Cui, J.; Yi, W.; Sun, Y. Crosstalk between macrophages and cardiac cells after myocardial infarction. Cell Commun. Signal. CCS 2023, 21, 109. [Google Scholar] [CrossRef]
- Sun, Y.; Pinto, C.; Camus, S.; Duval, V.; Alayrac, P.; Zlatanova, I.; Loyer, X.; Vilar, J.; Lemitre, M.; Levoye, A.; et al. Splenic Marginal Zone B Lymphocytes Regulate Cardiac Remodeling After Acute Myocardial Infarction in Mice. J. Am. Coll. Cardiol. 2022, 79, 632–647. [Google Scholar] [CrossRef]
- Zhu, Y.; Yang, W.; Wang, H.; Tang, F.; Zhu, Y.; Zhu, Q.; Ma, R.; Jian, Z.; Xiao, Y. Hypoxia-primed monocytes/macrophages enhance postinfarction myocardial repair. Theranostics 2022, 12, 307–323. [Google Scholar] [CrossRef]
- Lindsey, M.L.; Brunt, K.R.; Kirk, J.A.; Kleinbongard, P.; Calvert, J.W.; de Castro Brás, L.E.; DeLeon-Pennell, K.Y.; Del Re, D.P.; Frangogiannis, N.G.; Frantz, S.; et al. Guidelines for in vivo mouse models of myocardial infarction. Am. J. Physiol. Heart Circ. Physiol. 2021, 321, H1056–H1073. [Google Scholar] [CrossRef] [PubMed]
- Ojha, N.; Dhamoon, A.S. Myocardial Infarction. In StatPearls; StatPearls Publishing: Treasure Island, FL, USA, 2025. Available online: http://www.ncbi.nlm.nih.gov/books/NBK537076/ (accessed on 10 October 2025).
- Burke, R.M.; Villar, K.N.B.; Small, E.M. Fibroblast contributions to ischemic cardiac remodeling. Cell. Signal. 2021, 77, 109824. [Google Scholar] [CrossRef]
- Daseke, M.J.; Tenkorang, M.A.A.; Chalise, U.; Konfrst, S.R.; Lindsey, M.L. Cardiac Fibroblast Activation during Myocardial Infarction Wound Healing. Matrix Biol. J. Int. Soc. Matrix Biol. 2020, 91–92, 109–116. [Google Scholar] [CrossRef] [PubMed]
- Yang, J.; Yang, X.-S.; Fan, S.-W.; Zhao, X.-Y.; Li, C.; Zhao, Z.-Y.; Pei, H.-J.; Qiu, L.; Zhuang, X.; Yang, C.-H. Prognostic value of microRNAs in heart failure. Medicine 2021, 100, e27744. [Google Scholar] [CrossRef]
- Wang, W.; Zheng, H. Myocardial Infarction: The Protective Role of MiRNAs in Myocardium Pathology. Front. Cardiovasc. Med. 2021, 8, 631817. [Google Scholar] [CrossRef]
- Wang, Y.; Chen, L.; Wang, L.; Pei, G.; Cheng, H.; Zhang, Q.; Wang, S.; Hu, D.; He, Y.; He, C.; et al. Pulsed Electromagnetic Fields Combined with Adipose-Derived Stem Cells Protect Ischemic Myocardium by Regulating miR-20a-5p/E2F1/p73 Signaling. Stem Cells 2023, 41, 724–737. [Google Scholar] [CrossRef]
- Zhang, M.-W.; Shen, Y.-J.; Shi, J.; Yu, J.-G. MiR-223-3p in Cardiovascular Diseases: A Biomarker and Potential Therapeutic Target. Front. Cardiovasc. Med. 2021, 7, 610561. [Google Scholar] [CrossRef]
- Gao, F.; Kataoka, M.; Liu, N.; Liang, T.; Huang, Z.-P.; Gu, F.; Ding, J.; Liu, J.; Zhang, F.; Ma, Q.; et al. Therapeutic role of miR-19a/19b in cardiac regeneration and protection from myocardial infarction. Nat. Commun. 2019, 10, 1802. [Google Scholar] [CrossRef]
- Singh, S.; de Ronde, M.W.J.; Kok, M.G.M.; Beijk, M.A.; De Winter, R.J.; van der Wal, A.C.; Sondermeijer, B.M.; Meijers, J.C.M.; Creemers, E.E.; Pinto-Sietsma, S.-J. MiR-223-3p and miR-122-5p as circulating biomarkers for plaque instability. Open Heart 2020, 7, e001223. [Google Scholar] [CrossRef]
- Hänninen, M.; Jäntti, T.; Tolppanen, H.; Segersvärd, H.; Tarvasmäki, T.; Lassus, J.; Vausort, M.; Devaux, Y.; Sionis, A.; Tikkanen, I.; et al. Association of miR-21-5p, miR-122-5p, and miR-320a-3p with 90-Day Mortality in Cardiogenic Shock. Int. J. Mol. Sci. 2020, 21, 7925. [Google Scholar] [CrossRef]
- Scărlătescu, A.I.; Micheu, M.M.; Popa-Fotea, N.-M.; Dorobanțu, M. MicroRNAs in Acute ST Elevation Myocardial Infarction-A New Tool for Diagnosis and Prognosis: Therapeutic Implications. Int. J. Mol. Sci. 2021, 22, 4799. [Google Scholar] [CrossRef]
- Chalise, U.; Becirovic-Agic, M.; Lindsey, M.L. The cardiac wound healing response to myocardial infarction. WIREs Mech. Dis. 2023, 15, e1584. [Google Scholar] [CrossRef]
- Qiao, L.; Hu, S.; Liu, S.; Zhang, H.; Ma, H.; Huang, K.; Li, Z.; Su, T.; Vandergriff, A.; Tang, J.; et al. microRNA-21-5p dysregulation in exosomes derived from heart failure patients impairs regenerative potential. J. Clin. Investig. 2019, 129, 2237–2250. [Google Scholar] [CrossRef] [PubMed]
- Khalaji, A.; Mehrtabar, S.; Jabraeilipour, A.; Doustar, N.; Rahmani Youshanlouei, H.; Tahavvori, A.; Fattahi, P.; Alavi, S.M.A.; Taha, S.R.; Fazlollahpour-Naghibi, A.; et al. Inhibitory effect of microRNA-21 on pathways and mechanisms involved in cardiac fibrosis development. Ther. Adv. Cardiovasc. Dis. 2024, 18, 17539447241253134. [Google Scholar] [CrossRef] [PubMed]
- Bejerano, T.; Etzion, S.; Elyagon, S.; Etzion, Y.; Cohen, S. Nanoparticle Delivery of miRNA-21 Mimic to Cardiac Macrophages Improves Myocardial Remodeling after Myocardial Infarction. Nano Lett. 2018, 18, 5885–5891. [Google Scholar] [CrossRef] [PubMed]
- Haizler, A.; Loutati, R.; Taha, L.; Karmi, M.; Deeb, D.; Manassra, M.; Fink, N.; Sabouret, P.; Rana, J.S.; Mamas, M.A.; et al. Kinetics of High-Sensitive Cardiac Troponin I in Patients with ST-Segment Elevation Myocardial Infarction and Non-ST Segment Elevation Myocardial Infarction. Diagnostics 2025, 15, 2390. [Google Scholar] [CrossRef]
- Ding, Z.; Liu, X.; Jiang, H.; Zhao, J.; Temme, S.; Bouvain, P.; Alter, C.; Rafii, P.; Scheller, J.; Flögel, U.; et al. A refined TTC assay precisely detects cardiac injury and cellular viability in the infarcted mouse heart. Sci. Rep. 2024, 14, 25214. [Google Scholar] [CrossRef] [PubMed]
- Vora, K.P.; Kumar, A.; Krishnam, M.S.; Prato, F.S.; Raman, S.V.; Dharmakumar, R. Microvascular Obstruction and Intramyocardial Hemorrhage in Reperfused Myocardial Infarctions. JACC Cardiovasc. Imaging 2024, 17, 795–810. [Google Scholar] [CrossRef] [PubMed]
- Kochav, J.D.; Kim, J.; Judd, R.; Kim, H.W.; Klem, I.; Heitner, J.; Shah, D.; Shenoy, C.; Farzaneh-Far, A.; Polsani, V.; et al. Ischemia-Mediated Dysfunction in Subpapillary Myocardium as a Marker of Functional Mitral Regurgitation. JACC Cardiovasc. Imaging 2021, 14, 826–839. [Google Scholar] [CrossRef]
- Jada, L.; Holtackers, R.J.; Martens, B.; Nies, H.M.J.M.; Van De Heyning, C.M.; Botnar, R.M.; Wildberger, J.E.; Ismail, T.F.; Razavi, R.; Chiribiri, A. Quantification of myocardial scar of different etiology using dark- and bright-blood late gadolinium enhancement cardiovascular magnetic resonance. Sci. Rep. 2024, 14, 5395. [Google Scholar] [CrossRef] [PubMed]




| Antibody | Reference | Dilution |
|---|---|---|
| HIF1-α | NB 100–105 | 1:20 |
| α-SMA | ab7817 | 1:200 |
| CD163 | ab182422 | 1:300 |
| CD3 | ab16669 | 1:100 |
| CD68 | ab125212 | 1:500 |
| Myeloperoxidase | PAS16672 | 1:75 |
| miRNA | Primer Sequence | Gene | Primers Sequences |
|---|---|---|---|
| miR-21-5p | UAGCUUAUCAGACUGAUGUUGA | Fibronectin 1 | F: GCCCTTACAGTTCCAAGTTCC |
| miR-23a-3p | AUCACAUUGCCAGGGAUUUCC | R: GCCTACATAACAACTCTTCTC | |
| miR-122-5p | UGGAGUGUGACAAUGGUGUUUG | VEGFA | F: AAAAACGAAAGCGCAGAAA |
| miR-148b-3p | UCAGUGCAUCACAGAACUUUGU | R: TTTCTCCGCTCTGAACAAGG | |
| miR-93-5p | CAAAGUGCUGUUCGUGCAGGUAG | Collagen 1α | F: GTGGAAACCTGATGTATGCT |
| miR-20a-5p | UAAAGUGCUUAUAGUGCAGGUAG | R: TGGTGATCATATTCTTCTGGG | |
| miR-107 | AGCAGCAUUGUACAGGGCUAUCA | CDH1 | F: AGAAGCCATGACAAGTACCT |
| miR-30b-5p | UGUAAACAUCCUACACUCAGCU | R: ACAGATCCCTCAAAGACCTC | |
| let-7a-5p | UGAGGUAGUAGGUUGUAUAGUU | Vimentin | F: CCTGCTCAATGTAAAGATGG |
| miR-144-3p | UACAGUAUAGAUGAUGUACU | R: GGTGTCAGTTGTTATGTGCT | |
| miR-27b-3p | UUCACAGUGGCUAAGUUCUGC | ||
| miR-221-3p | AGCUACAUUGUCUGCUGGGUUUC | ||
| miR-210-3p | CUGUGCGUGUGACAGCGGCUGA | ||
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2026 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.
Share and Cite
Rodríguez-Serrano, M.; Martín-García, E.; Alonso-Andrés, P.; Conde-Moreno, E.; Pian, H.; del Moral-Salmoral, J.; Alcharani, N.; Menacho-Román, M.; Crespo-Toro, L.; Ramos-Muñoz, M.E.; et al. Dynamic microRNA Signatures as Biomarkers for Cardiac Ischemia and Remodeling. Int. J. Mol. Sci. 2026, 27, 1488. https://doi.org/10.3390/ijms27031488
Rodríguez-Serrano M, Martín-García E, Alonso-Andrés P, Conde-Moreno E, Pian H, del Moral-Salmoral J, Alcharani N, Menacho-Román M, Crespo-Toro L, Ramos-Muñoz ME, et al. Dynamic microRNA Signatures as Biomarkers for Cardiac Ischemia and Remodeling. International Journal of Molecular Sciences. 2026; 27(3):1488. https://doi.org/10.3390/ijms27031488
Chicago/Turabian StyleRodríguez-Serrano, Macarena, Elena Martín-García, Patricia Alonso-Andrés, Elisa Conde-Moreno, Héctor Pian, Javier del Moral-Salmoral, Nunzio Alcharani, Miriam Menacho-Román, Lorena Crespo-Toro, Miren Edurne Ramos-Muñoz, and et al. 2026. "Dynamic microRNA Signatures as Biomarkers for Cardiac Ischemia and Remodeling" International Journal of Molecular Sciences 27, no. 3: 1488. https://doi.org/10.3390/ijms27031488
APA StyleRodríguez-Serrano, M., Martín-García, E., Alonso-Andrés, P., Conde-Moreno, E., Pian, H., del Moral-Salmoral, J., Alcharani, N., Menacho-Román, M., Crespo-Toro, L., Ramos-Muñoz, M. E., Zaragoza, C., Rincón, L. M., Barderas, M. G., & García-Bermejo, M. L. (2026). Dynamic microRNA Signatures as Biomarkers for Cardiac Ischemia and Remodeling. International Journal of Molecular Sciences, 27(3), 1488. https://doi.org/10.3390/ijms27031488

